This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Helmholtz-Zentrum Dresden-Rossendorf - Institute of Radiopharmaceutical Cancer Research, Instituto Portugues De Oncologia Do Porto Fg, Epe, Universidade Nova De Lisboa. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1 
1 out of 1 
1 out of 7 Years Active: 2022
Title: The Innovative Journey of Mylène Adelaide Do Rosário Carrascal
Introduction
Mylène Adelaide Do Rosário Carrascal, a prominent inventor based in Caparica, Portugal, has made significant contributions to cancer research through his innovative work in antibody technology. His dedication to advancing medical science has led him to develop a groundbreaking patent that could enhance the detection, treatment, and prevention of human diseases, particularly cancer.
Latest Patents
Mr. Carrascal holds a significant patent for the L2A5 antibody or functional fragments thereof, which are directed against tumor antigens. This invention encompasses antibody or functional antibody fragments aimed at a unique group of antigens associated with cancer. It includes nucleotide sequences derived from the L2A5 monoclonal antibody, featuring a variable heavy chain domain and a variable light chain domain with a specific amino acid sequence, which is unique and unprecedented in the field. The invention may potentially revolutionize approaches in diagnosing and treating cancer, marking a critical step forward in cancer therapeutics.
Career Highlights
In addition to his inventiveness, Mylène has an impressive background with esteemed institutions. He has worked at Universidade Nova De Lisboa and the Instituto Português De Oncologia Do Porto, Fg, Epe, contributing to important research initiatives and collaborations that underline his commitment to improving healthcare through scientific advancements.
Collaborations
Throughout his career, Mr. Carrascal has partnered with notable colleagues, including Paula Alexandra Quintela Videira and Carlos Manuel Mendes Novo. Their collaborative efforts exemplify the spirit of teamwork in scientific research, driving innovation and discovery in oncology.
Conclusion
Mylène Adelaide Do Rosário Carrascal represents a dynamic force in the field of medical research, particularly in cancer therapeutics. His invention of the L2A5 antibody is a testament to his dedication to combatting human disease through innovation. With ongoing collaborations and a strong career foundation, Carrascal continues to pave the way for future breakthroughs in the medical field, making a lasting impact on health sciences.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile